EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Molecular Markers in the Era of Precision Care in Lung Cancer

Ishan Paranjpe, Alexander I Salter, Kenneth Chen, Millie Das

Seminars in Respiratory and Critical Care Medicine · 01.10.2025 · 46 (05) · 396-408

DOI: 10.1055/a-2649-9199 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Seminars in Respiratory and Critical Care Medicine, erschienen am 01.10.2025. Verfasst von Ishan Paranjpe und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Stanford University School of Medicine, Stanford, California. Hauptthemen laut MEDLINE: Lung Neoplasms, Precision Medicine, Carcinoma, Non-Small-Cell Lung, Molecular Targeted Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 162 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths worldwide. The past two decades have brought advances in molecular profiling and the advent of therapies that specifically target genetic and/or molecular alterations in NSCLC. There are now many FDA-approved targeted therapies for patients with metastatic lung cancer who harbor oncogenic driver alterations, including those in epidermal growth factor receptor, ALK receptor tyrosine kinase, KRAS proto-oncogene, GTPase, and others. These advances epitomize personalized medicine and improve patient outcomes compared with conventional cytotoxic chemotherapy. This review highlights the current and evolving landscape of targeted therapies in NSCLC, emphasizing key targets, resistance mechanisms, and new approaches poised to improve patient outcomes in the era of precision oncology. The next decade will likely be marked by further improvements in the specificity, duration of action, and toxicity profiles of targeted therapies, allowing patients to live longer and better lives.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsPrecision MedicineCarcinoma, Non-Small-Cell LungMolecular Targeted TherapyBiomarkers, TumorHumansProto-Oncogene MasErbB ReceptorsAntineoplastic AgentsAnaplastic Lymphoma KinaseProto-Oncogene Proteins p21(ras)Drug Resistance, Neoplasm

Substanzen

Proto-Oncogene MasMAS1 protein, humanBiomarkers, TumorErbB ReceptorsAntineoplastic AgentsAnaplastic Lymphoma KinaseKRAS protein, humanProto-Oncogene Proteins p21(ras)

Autor:innen und Institutionen

  • Department of Medicine, Stanford University School of Medicine, Stanford, California.
  • Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California.
  • Division of Oncology, Department of Medicine, Veterans Affairs Palo Alto Health System, Palo Alto, California.

Zitieren

APA

Paranjpe, I., Salter, A. I., Chen, K., & Das, M. (2025). Molecular Markers in the Era of Precision Care in Lung Cancer. Seminars in Respiratory and Critical Care Medicine, 46(05), 396-408. https://doi.org/10.1055/a-2649-9199

Vancouver

Paranjpe I, Salter AI, Chen K, Das M. Molecular Markers in the Era of Precision Care in Lung Cancer. Seminars in Respiratory and Critical Care Medicine. 2025;46(05):396-408. doi:10.1055/a-2649-9199

BibTeX
@article{Paranjpe2025,
  author = {Paranjpe, Ishan and Salter, Alexander I and Chen, Kenneth and Das, Millie},
  title = {Molecular Markers in the Era of Precision Care in Lung Cancer},
  journal = {Seminars in Respiratory and Critical Care Medicine},
  year = {2025},
  volume = {46},
  number = {05},
  pages = {396--408},
  doi = {10.1055/a-2649-9199}
}
Kostenlos starten →